Document is current

Article History

Accepted: 17 February 2021

First Online: 24 March 2021

Competing interests

: M.S.M. has become an employee of AstraZeneca since this manuscript was initiated, and is a current shareholder of this company; however, this affiliation does not lead to a direct conflict of interest with the presented work. P.W. is a consultant and/or scientific advisory board member for Astex Pharmaceuticals, Black Diamond Therapeutics, CV6, NextechInvest and Storm Therapeutics, and holds stock in Black Diamond Therapeutics, Chroma Therapeutics, NextechInvest and Storm Therapeutics; he is also a former employee of AstraZeneca and a Non-Executive Director of Storm Therapeutics and the Royal Marsden NHS Trust, and is an Executive Director of the non-profit Chemical Probes Portal. P.W. has received research funding from CRT Pioneer Fund/6^th Element Capital and Merck. J.d.B. has served on advisory boards for Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi, Eisai, Genentech/Roche, Genmab, GlaxoSmithKline, Janssen, Merck Serono, Merck Sharp & Dohme, Menarini Silicon Biosystems, Orion, Pfizer, Qiagen, Sanofi-Aventis, Sierra Oncology, Taiho and Vertex Pharmaceuticals. He is an employee of The Institute of Cancer Research, which has received funding or other support for his research work from Astellas, AstraZeneca, Bayer, Cellcentric, Daiichi, Genentech, Genmab, GlaxoSmithKline, Janssen, Merck Serono, Merck Sharp & Dohme, Menarini Silicon Biosystems, Orion, Pfizer, Sanofi-Aventis, Sierra Oncology, Taiho and Vertex. The Institute of Cancer Research also has a commercial interest in abiraterone, PARP inhibition in DNA repair-defective cancers and PI3K/AKT pathway inhibitors (which provide no personal income to J.d.B.). J.d.B. is named as an inventor, with no financial interest, on US patent 8,822,438. A.P. and R.S. declare no competing interests.